Natural Sinus Rinse

The primary purpose of the study was to investigate the anti-inflammatory effects of cannabidiol and Cannabigerol (CBG) in a model of inflammation in the respiratory tract induced by bacterial lipopolysaccharide (LPS) exposure, which subsequently triggers an inflammatory cascade of events that includes a rise in inflammatory cell count (leukocytes, specifically neutrophils needed to fight infections).

As seen in the figure here, there is a dose-dependent decrease in total inflammatory leukocyte cell count in the respiratory tract as compared to the control vehicle in response to
administration of Cannabigerol (CBG).
Conclusion: Cannabigerol (CBG) formulated appropriately can exhibit and promote
anti-inflammatory activity in the respiratory tract.

Cannabidiol (CBD) and cannabigerol (CBG) are two pharmacologically active phytocannabinoids. Their antimicrobial activity needs further elucidation, particularly for CBG. We investigated CBD and CBG’s antimicrobial potential, including their ability to inhibit the formation and cause the removal of biofilms. Our results demonstrate that both molecules present activity against planktonic bacteria and biofilms, with both cannabinoids removing mature biofilms at concentrations below the determined minimum inhibitory concentrations. We report for the first time minimum inhibitory and lethal concentrations for Pseudomonas aeruginosa and Escherichia coli (ranging from 400 to 3180 µM), as well as the ability of cannabinoids to inhibit Staphylococci adhesion to keratinocytes, with CBG demonstrating higher activity than CBD. Further, the exact formulation showed no negative impact on skin microbiota. Our results suggest that phytocannabinoids can be promising topical antimicrobial agents when searching for novel therapeutic candidates.

"The results of this study suggest that a higher frequency of cannabis use is associated with a lower likelihood of sinonasal symptoms."